| Literature DB >> 26871471 |
Zhiyu Wang1, Xiaoting Wen1, Yaohong Lu1, Yang Yao1, Hui Zhao1.
Abstract
The aim of the bone metastases (BM) treatment is to prevent the occurrence of skeletal-related events (SREs). In clinical, physicians could only predict the occurrence of SREs by subjective experience. Machine learning (ML) could be used as predictive models in the medical field. But there is no published research using ML to predict SREs in cancer patients with BM. The purpose of this study was to assess the associations of clinical variables with the occurrence of SREs and to subsequently develop prediction models to help identify SREs risk groups.We analyzed 1143 cancer patients with BM. We used the statistical package of SPSS and SPSS Modeler for data analysis and the development of the prediction model. We compared the performance of logistic regression (LR), decision tree (DT) and support vector machine(SVM). The results suggested that Visual Analog Scale (VAS) scale was a key factor to SREs in LR, DT and SVM model. Modifiable factors such as Frankel classification, Mirels score, Ca, aminoterminal propeptide of type I collagen (PINP) and bone-specific alkaline phosphatase (BALP) were identified. We found that the result of applying LR, DT and SVM classification accuracy was 79.2%, 85.8% and 88.2%, with 9, 4 and 8 variables, respectively.In conclusion, DT and SVM achieved higher accuracies with smaller number of variables than the number of variables used in LR. ML techniques can be used to build model to predict SREs in cancer patients with BM.Entities:
Keywords: bone metastases; decision tree; machine learning; skeletal-related events; support vector machine
Mesh:
Year: 2016 PMID: 26871471 PMCID: PMC4914308 DOI: 10.18632/oncotarget.7278
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Baseline characteristics of patients
| Variables | All patients | With SREs | Without SREs |
|---|---|---|---|
| Gender (1/2) | 614/529 | 382/240 | 232/289 |
| Age (mean ± SD) | 59.9 ± 23.7 | 58.8 ± 11.6 | 61.3 ± 32.8 |
| KPS Scale (1/2) | 969/174 | 515/107 | 454/67 |
| VAS scale(1/2/3) | 270/444/429 | 69/191/362 | 201/253/67 |
| Character of BM (1/2/3) | 917/83/143 | 517/34/71 | 400/49/72 |
| The extent of BM (1/2/3) | 178/610/355 | 108/316/198 | 70/294/157 |
| Visceral metastases (1/2) | 623/520 | 347/275 | 276/245 |
| Frankel classification (1/2/3/3/5) | 20/20/56/58/843 | 20/19/47/47/418 | 0/1/9/11/425 |
| Mirels (1/2/3) | 38/228/25 | 13/132/22 | 25/96/3 |
| β-CTX (mean ± SD) | 772.9 ± 488.4 | 810.5 ± 548.2 | 741.6 ± 430.2 |
| N-MID (mean ± SD) | 22.4 ± 40.1 | 24.4 ± 45.3 | 20.8 ± 35.0 |
| PINP (mean ± SD) | 166.3 ± 156.5 | 195.8 ± 193.3 | 141.7 ± 111.8 |
| BALP (mean ± SD) | 35.7 ± 25.4 | 35.8 ± 26.0 | 35.5 ± 24.6 |
| CEA (mean ± SD) | 173.4 ± 569.1 | 203.8 ± 499.0 | 148.0 ± 620.8 |
| CA125 (mean ± SD) | 171.8 ± 473.3 | 195.6 ± 592.6 | 143.3 ± 265.1 |
| CA153 (mean ± SD) | 91.1 ± 213.0 | 91.9 ± 205.9 | 90.4 ± 218.9 |
| CA199 (mean ± SD) | 299.5 ± 1034.9 | 347.0 ± 1196.2 | 259.8 ± 877.3 |
| AKP(mean ± SD) | 184.7 ± 217.0 | 194.4 ± 241.5 | 176.6 ± 194.0 |
| Ca (1/2) | 1091/52 | 570/52 | 521/0 |
Among 997 patient with spine metastasis, 551 with SREs, 446 without SREs.
Among 291 patient with extremity metastasis, 167 with SREs, 124 without SREs.
Summary of SREs in the study
| SREs | People | Times |
|---|---|---|
| Total confirmed events | 973 | 1123 |
| Radiation to bone | 347 (35.7%) | 464 (41.3%) |
| Pathological fracture | 248 (25.4%) | 263 (23.4%) |
| Spinal cord compression | 97 (10.0%) | 97 (8.6%) |
| Surgery to bone | 229 (23.6%) | 245 (21.8%) |
| Hypercalcemia | 52 (5.3%) | 54 (4.9%) |
Summary of cancer type and SREs in the study
| Cancer type | All (%) | With SREs | Without SREs |
|---|---|---|---|
| Lung cancer | 566 (49.5%) | 256 (45.2%) | 310 (54.8%) |
| Breast cancer | 173 (15.1%) | 115 (66.5%) | 58 (33.5%) |
| Prostate cancer | 71 (6.2%) | 37 (52.1%) | 34 (47.9%) |
| Urinary cancer | 56 (4.9%) | 38 (67.9%) | 18 (32.1%) |
| Colorectal cancer | 54 (4.7%) | 32 (59.3%) | 22 (40.7%) |
| Esophagus and stomach cancer | 40 (3.5%) | 20 (50.0%) | 20 (50.0%) |
| Liver cancer | 35 (3.1%) | 29 (82.9%) | 6 (17.1%) |
| Nasopharyngeal cancer | 20 (1.7%) | 12 (60.0%) | 8 (40.0%) |
| Thyroid cancer | 16 (1.4%) | 11 (68.8%) | 5 (31.2%) |
| Gynecologic cancer | 16 (1.4%) | 12 (75.0%) | 4 (25.0%) |
| Cancer of unknown primary | 78 (6.8%) | 46 (59.0%) | 32 (41.05) |
| Other cancer | 18 (1.6%) | 14 (77.8%) | 4 (22.2%) |
LR model of SREs in patients with BM
| Variable | Coefficient | SE | |
|---|---|---|---|
| VAS scale | |||
| 1 | −3.16 | 0.24 | < 0.01 |
| 2 | −2.27 | 0.21 | < 0.01 |
| 3 | −0.43 | 0.18 | < 0.01 |
| Mirels score | |||
| 1 | −2.58 | 0.89 | 0.24 |
| 2 | −2.57 | 0.97 | 0.41 |
| 3 | −2.43 | 0.89 | 0.31 |
| Gender | |||
| 1 | 1.65 | 0.21 | 0.22 |
| Cancer type | |||
| 1 | −0.01 | 0.82 | 0.46 |
| 2 | 2.67 | 0.85 | 0.17 |
| 3 | −0.04 | 0.87 | 0.96 |
| 4 | 0.19 | 0.89 | 0.83 |
| 5 | 0.48 | 0.88 | 0.58 |
| 6 | 0.66 | 0.97 | 0.49 |
| 7 | 0.93 | 1.00 | 0.35 |
| 8 | −0.33 | 1.03 | 0.75 |
| 9 | 1.31 | 1.10 | 0.23 |
| 10 | 0.97 | 1.09 | 0.37 |
| 11 | 0.01 | 0.88 | 0.98 |
| Frankel classification | |||
| 1 | −5.86 | 0.40 | < 0.01 |
| 2 | −5.42 | 0.45 | < 0.01 |
| 3 | −4.25 | 0.37 | < 0.01 |
| 4 | −4.65 | 0.38 | < 0.01 |
| 5 | −3.29 | 0.52 | < 0.01 |
| PINP | −0.01 | 0.01 | 0.07 |
| BALP | 0.03 | 0.02 | 0.36 |
| β-CTx | −0.01 | 0.01 | 0.54 |
| Ca | |||
| 1 | −1.21 | 0.05 | 0.02 |
| Constant | 5.74 | 0.92 | 0.63 |
SE: standard error, CI: confidence interval.
Figure 1DT model of SREs in patients with BM
Combination of the top eight variables and classification accuracy in SVM
| No. of variables | Combined variables in ranking order | Accuracy (%) |
|---|---|---|
| 1 | VAS scale | 55.1 |
| 2 | VAS scale, Frankel classification | 67.4 |
| 3 | VAS scale, Frankel classification, Ca | 76.6 |
| 4 | VAS scale, Frankel classification, Ca, Cancer type | 84.3 |
| 5 | VAS scale, Frankel classification, Ca, Cancer type, Gender | 91.7 |
| 6 | VAS scale, Frankel classification, Ca, Cancer type, Gender, Mirels score | 94.4 |
| 7 | VAS scale, Frankel classification, Ca, Cancer type, Gender, Mirels score, PINP | 96.2 |
| 8 | VAS scale, Frankel classification, Ca, Cancer type, Gender, Mirels score, PINP, Character of BM | 97.1 |
Comparison between LR, DT and SVM
| Model | Predicted positive | Predicted negative | Accuracy (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|
| 79.2 | 79.4 | 78.9 | 81.8 | 76.3 | |||
| 494 | 128 | ||||||
| 110 | 411 | ||||||
| 85.8 | 87.9 | 83.3 | 86.2 | 85.3 | |||
| 547 | 75 | ||||||
| 87 | 434 | ||||||
| 88.2 | 88.6 | 87.7 | 89.6 | 86.5 | |||
| 551 | 71 | ||||||
| 64 | 457 |
PPV: positive predictive value, NPV: negative predictive value.
Comparison of AUC between LR, DT and SVM
| Model | AUC | SE | 95% CI for Exp (B) | |
|---|---|---|---|---|
| Lower | Upper | |||
| LR | 0.792 | 0.012 | 0.767 | 0.815 |
| DT | 0.856 | 0.011 | 0.835 | 0.876 |
| SVM | 0.882 | 0.010 | 0.861 | 0.900 |
Summary of attributes included in the study
| Attribute | Represented as {permissible value} |
|---|---|
| Gender | Categorical { Male (1) / Female (2) } |
| Age | Numeric |
| KPS Scale | Categorical { ≥ 70 (1) / < 60 (2) } |
| VAS scale | Categorical { Grade 1 (1) / 2 (2) / 3 (3) } |
| Character of BM | Categorical { Lytic (1) / Blastic (2) / Mixed (3) } |
| The extent of BM | Categorical { Soloway 1 (1) / 2 (2) / 3–4 (3) } |
| Visceral metastases | Categorical { Without (1) / With(2) } |
| Frankel classification | Categorical { A (1) / B (2) / C (3) / D (4) / E (5) / Without spine metastasis (6) } |
| Mirels scale | Categorical { Without extremity metastasis (0) / 4–6 (1) / 7–9 (2) / 10–12 (3) } |
| β-CTX | Numeric |
| N-MID | Numeric |
| PINP | Numeric |
| BALP | Numeric |
| CEA | Numeric |
| CA125 | Numeric |
| CA153 | Numeric |
| CA199 | Numeric |
| AKP | Numeric |
| Ca | Categorical { ≥ 2.6 mmol/l (1) / < 2.6 mmol/l (2) } |
Pain level on a 10-point scale, with 0 representing no pain and 10 representing the maximum pain intensity imaginable. Grade 1: 0–3, Grade 2: 4–6, Grade 3: 7–10.
Soloway 0 refers to patients without BM; Soloway 1 refers to patients with < 6 BM; Soloway 2 refers to patients with < 20 BM; Soloway 3 refers to patients with > 20 but less than a “super scan”; Soloway 4 refers to patients with “super scan” that is defined by a > 75% involvement of the ribs, vertebrae, and pelvic bones [19].
Visceral metastases defined as distant metastases, except for BM, including brain metastases.
Frankel classification of spinal cord injury [20]: Class A representing complete paralysis, Class B representing sensory function only below the injury level, Class C representing incomplete motor function below injury level, Class D representing fair to good motor function below injury level, and Class E representing normal function.
Mirels scoring system [21] based on pain intensity, site, type (lytic, mixed or blastic) and amount of bony involvement.